In conclusion, in a subset of patients with advanced HCC treated with the novel TGF-βRI/ALK5 inhibitor galunisertib, decreases in circulating AFP and TGF-β1 levels were associated with longer OS. The gene discussed is TGFBR1; the disease is hepatocellular carcinoma.